LASIK eye surgery costs roughly $2,100 per eye today. In 1998, it cost $2,200 per eye. Adjusted for inflation, you are paying about 60% less for a procedure that has simultaneously become faster, safer, and more precise. That is what markets do when left alone. Now compare that to a hearing aid. The FDA classified hearing aids as prescription medical devices for decades, locking you into audiologist appointments before you could buy a $3,000 device that a manufacturer could produce for $300. Or, look at insulin. Heavily regulated, patent-extended, and politically manipulated, a vial of Humalog ran over $330 in 2024 versus roughly $21 in Canada for a biosimilar. Same molecule. Different regulatory environment. LASIK sits in a peculiar gap. Insurers rarely cover it, which means third-party payment schemes never severed the price signal between provider and patient. You shop, clinics compete, manufacturers race to improve technology. The feedback loop that markets depend on functions exactly as it should. Regulated medical markets break that loop deliberately. The FDA's approval process costs pharmaceutical companies over $2.6 billion per new drug on average, erecting barriers that protect incumbents and punish smaller competitors who cannot absorb a decade of compliance costs. Patients then pay the premium on the back end. LASIK is the control in the experiment. The market won.